Larry Lei Xiao

Citigroup Global Markets, Inc. (Broker) (CGMI-Broker) is the broker/dealer division of Citigroup Global Markets, Inc., an investment bank headquartered in New York City with additional offices across the US. The firm was founded in 2004 and is a subsidiary of Citigroup Financial Products, Inc., ultimately held by Citigroup, Inc. (NYSE: C). CGMI-Broker covers all market capitalizations of the major global indices and provides macro and quantitative analysis of global markets and sector trends. Their core focus of the group is to help investing clients make informed decisions by providing value-added, independent, insightful analysis.

Part of Franklin Resources, Inc., Lehman Brothers Global Asset Management is an American asset management company. The company is based in NY. Lehman Brothers Global Asset Management was acquired by Legg Mason, Inc., a subsidiary of Franklin Resources, Inc. from Lehman Brothers Holdings, Inc. on February 13, 1996 for $10 million.

Lazard Asset Management LLC (LAM) is a SEC-registered investment advisor headquartered in New York City. The firm was founded in 1970 and is a wholly-owned subsidiary of Lazard Frères & Co. LLC, ultimately held by Lazard Ltd. (NYSE: LAZ). LAM provides investment advisory services to a variety of clients.

Inventia Healthcare Ltd. engages in the development and manufacture of pharmaceutical formulations. It caters anti-diabetic, gastrointestinal, CVC, CNS and musculoskeletal therapeutic areas. The company was founded by Janak Shah and Maya Shah in 1985 and is headquartered in Mumbai, India.

Innovative Cellular Therapeutics Co., Ltd. is a Chinese private clinical stage biotechnology company headquartered in an undisclosed location. Innovative Cellular Therapeutics is focused on the development of cellular immunotherapies for the treatment of solid tumors, using their unique CoupledCAR® technology platform. The company has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and prostate cancer, and has a broad pipeline of CAR-T candidates targeting additional solid tumors. The company was founded in 2009 by Zhao Wu and Lei Xiao, with Lei Xiao serving as the CEO since then.